/Incyte%20Corp_%20phone%20and%20logo-by%20T_Schneider%20via%20Shutterstock.jpg)
With a market cap of $19 billion, Incyte Corporation (INCY) is a Delaware–based biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies, primarily in oncology and inflammatory diseases. The company specializes in small-molecule drugs that modulate specific biological pathways, particularly those involved in cancer and immune system disorders.
The company is set to unveil its fiscal Q1 2026 results before the market opens on Tuesday, Apr. 28. Ahead of this event, analysts expect INCY to report a profit of $1.21 per share, up 36% from $0.89 per share in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarters while missing on another occasion.